GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

By A. Gilmartin, Maureen R. Bleam, Arthur Groy, K. Moss, E. Minthorn, S. Kulkarni, Cynthia M. Rominger, S. Erskine, K. Fisher, Jingsong Yang and 4 more. Clinical Cancer Research, 2011

597 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/621d97ef35e73806fd63c3c43597318a224c7560

Citations in the corpus

• Dynamic Reprogramming of the Kinome In Response to Targeted MEK Inhibition In Triple Negative Breast Cancer (2012, unknown): “Published work with a similar MEK inhibitor, GSK1120212, which binds to the MEK allosteric regulatory site (as does AZD6244) provides insight into how MEK2 escapes inhibition (Gilmartin et al., 2011).”